Confo Therapeutics is awarded a EUR 1M grant to increase its screening capabilities
Confo Therapeutics announced today that it has received a €1 million grant from the Flemish Government through Flanders Innovation & Entrepreneurship (VLAIO). The grant will be used to support the development of new methods for screening libraries of small molecules for the discovery of new therapeutic candidates targeting G-protein coupled receptors (GPCRs), using the company’s proprietary conformation-sensitive single domain antibodies or Confobodies.
Commenting on the grant, Dr. Cedric Ververken, CEO, said: “Once again we are grateful for the financial support by VLAIO totaling €1 million over 16 months. The grant will support the continued development of our GPCR screening capabilities.”
Dr. Christel Menet, CSO, added: “The goal of this project is to develop unique proprietary Confobody-based screening technologies providing a ‘next generational’ improvement in performance over current GPCR screening approaches. These new methods will be highly complementary to our current Confoscreen assays and will thereby maximize our overall chance of success in discovering therapeutic candidates to previously ‘undruggable’ GPCRs.”